Skip to main content
SpringerLink
Log in

Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Solitary plasmacytoma of bone (SPB) is a rare tumor that represents a minority of patients with plasma cell localized malignancy characterized by a single osteolytic bone lesion. The molecular mechanism underlying the genesis of SPB has remained enigmatic. Signal transducers and activators of transcription-3 (STAT3) is often activated in human cancers and is implicated in tumorigenesis. In the present work, the immunohistochemical expression of pSTAT3 (the active isoform of STAT3) and its potential downstream mediators (Bcl-2, Bcl-xL, c-Myc, cyclin D1, VEGF, cIAP-2, Mcl-1, and survivin) were examined, clinical features were investigated, and relative prognostic factors were analyzed. Positive expression of Bcl-2 was observed in 46.7 % (14/30) of patients, c-Myc in 36.7 % (11/30), and cyclin D1 in 23.3 % (7/30). By univariate analysis, Bcl-2 expression was found to be closely associated with shorter overall survival (OS) and progression-free survival. Bcl-2 and c-Myc positive expression were also found to be a factor that affect time to progression to multiple myeloma. In conclusion, results showed Bcl-2 expression to be a clinically significant prognostic indicator for SPB patients and constitutive activated STAT3 may not be the sole primary regulatory mechanism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY et al (2012) A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J 2012:895765

    Article  Google Scholar 

  2. Lorsbach RB, Hsi ED, Dogan A et al (2011) Plasma cell myeloma and related neoplasms. Am J Clin Pathol 136(2):168–182

    Article  PubMed  Google Scholar 

  3. Dimopoulos MA, Moulopoulos LA, Maniatis A et al (2000 Sep 15) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96(6):2037–2044

    Google Scholar 

  4. Phromnoi K, Prasad S, Gupta SC et al (2011) Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1. Mol Pharmacol 80(5):889–899

    Article  CAS  PubMed  Google Scholar 

  5. Liang P, Cheng SH, Cheng CK et al (2013) Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myeloma. Haematologica 98(2):288–295

    Article  CAS  PubMed  Google Scholar 

  6. Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296–303

    Article  CAS  PubMed  Google Scholar 

  7. Hasegawa T, Suzuki K, Sakamoto C et al (2003) Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 101(3):1164–1171

    Article  CAS  PubMed  Google Scholar 

  8. Aggarwal BB, Sethi G, Ahn KS et al (2006) Targeting signal transducer and activator of transcription 3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091:151–169

    Article  CAS  PubMed  Google Scholar 

  9. SH Swerdlow EC, Harris NL, et al. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer (IARC) Lyon, France

  10. Hughes M, Soutar R, Lucraft H et al (2009) Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas. British Committee for Standards in Haematology, London, 14 p

    Google Scholar 

  11. Dingli D, Kyle RA, Rajkumar SV et al (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108(6):1979–1983

    Article  CAS  PubMed  Google Scholar 

  12. Soutar R, Lucraft H, Jackson G et al (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Clin Oncol (R Coll Radiol) 16(6):405–413

    Article  Google Scholar 

  13. Jyothirmayi R, Gangadharan VP, Nair MK et al (1997) Radiotherapy in the treatment of solitary plasmacytoma. Br J Radiol 70:511–516

    CAS  PubMed  Google Scholar 

  14. Dimopoulos MA, Hamilos G (2002) Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol 3:255–259

    Article  PubMed  Google Scholar 

  15. Weber DM (2005) Solitary bone and extramedullary plasmacytoma. Hematology 1:373–376

    Article  Google Scholar 

  16. Kim PJ, Hicks RJ, Wirth A et al (2009) Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys 74(3):740–746

    Article  CAS  PubMed  Google Scholar 

  17. Hu K, Yahalom J (2000) Radiotherapy in the management of plasma cell tumors. Oncol (Williston Park) 14(1):101–108

    CAS  Google Scholar 

  18. Chao MW, Gibbs P, Wirth A (2005) Radiotherapy in the management of solitary extramedullary plasmacytoma. Intern Med J 35(4):211–215

    Article  CAS  PubMed  Google Scholar 

  19. Suh YG, Suh CO, Kim JS et al (2012 Nov) Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors. Ann Hematol 91(11):1785–1793

    Google Scholar 

  20. Tsang RW, Gospodarowicz MK, Pintilie M (2001) Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys 50(1):113–120

    Article  CAS  PubMed  Google Scholar 

  21. Kilciksiz S, Celik OK, Pak Y et al (2008) Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party. Am J Hematol 83(9):702–707

    Article  PubMed  Google Scholar 

  22. Knobel D, Zouhair A, Tsang RW et al (2006) Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer 6:118

    Article  PubMed Central  PubMed  Google Scholar 

  23. Ozsahin M, Tsang RW, Poortmans P et al (2006) Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys 64(1):210–217

    Article  PubMed  Google Scholar 

  24. Zuo Z, Tang Y, Bi CF et al (2011) Extraosseous (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases. Diagn Pathol 6:123

    Article  PubMed Central  PubMed  Google Scholar 

  25. Visco C, Tzankov A, Xu-Monette ZY et al (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98(2):255–263

    Article  CAS  PubMed  Google Scholar 

  26. Zhang Y, Zhao X, Tao J (2012) Epigenetics, c-Myc and aggressive B-cell lymphomas. Oncotarget 3(11):1264–1265

    PubMed  Google Scholar 

  27. Rutsch S, Neppalli VT, Shin DM et al (2010) IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood 115(9):1746–1754

    Article  CAS  PubMed  Google Scholar 

  28. Khuda SE, Loo WM, Janz S et al (2008) Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. J Immunol 181(11):7537–7549

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Yang C, Lee H, Jove V et al (2013) Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One 8(1):e54029

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgment

We should acknowledge the support by two grants from the National Natural Science Foundation of China (No. 30672208 and No. 81270603).

Conflict of interest

The authors have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, People’s Republic of China

    Shanqi Guo, Yaqin Zhi, Hongliang Yang, Yong Yu, Yafei Wang & Yizhuo Zhang

  2. Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, 300060, People’s Republic of China

    Jin Zhang & Guowen Wang

  3. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin, 300060, People’s Republic of China

    Lianyu Zhang & Baocun Sun

Authors
  1. Shanqi Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaqin Zhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongliang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yafei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guowen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lianyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Baocun Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yizhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yizhuo Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, S., Zhi, Y., Yang, H. et al. Bcl-2 expression is associated with poor prognosis of solitary plasmacytoma of bone. Ann Hematol 93, 471–477 (2014). https://doi.org/10.1007/s00277-013-1897-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1897-8

Keywords

Search

Navigation